Nona Biosciences’ Post

Evaxion is attending Immuno 2024! Today, Jens Kringelum, Vice President of AI & Innovation at Evaxion, will speak at the 9th Annual Advances in Immuno-Oncology Congress in London, UK.   At 14:50 GMT, Jens will give a presentation titled “Personalised Cancer Vaccines: Levering hERVs as Vaccine Targets to Overcome Limitations in Low-Mutational Burden Cancers.” His talk will cover Evaxions’ innovative use of human endogenous retroviruses (hERVs) to develop new types of cancer vaccines that could help address hard-to-treat indications. The promising results from our ObsERV™ model underscore the potential of our AI-Immunology™ platform for developing new treatment possibilities for saving and improving patients’ lives.   Soon after, at 16:30 GMT, Jens will participate in a panel discussion on clinical development case studies, sharing insights from our latest research. For more information about this event, please visit their site by following the link below.   #Immuno2024 #CancerResearch #Immunotherapy #AI #Vaccines #Innovation #Healthcare

Cancer Diagnostics Market Worth USD 26.6 billion 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/gyNZzbGp The global cancer diagnostics market size is projected to reach USD 26.6 billion by 2026 from USD 17.2 billion in 2021, at a CAGR of 11.5%. The growth in this market is attributed to the increasing incidence of cancer and increasing number of private diagnostic laboratories. #cancerdiagnostics #biopsy #IVD #diagnosticimaging GE HealthCare Becton, Dickinson and Company F. Hoffmann-La Roche Ltd Danaher Corporation Thermo Fisher Scientific Abbott QIAGEN Agilent Technologies Illumina Siemens Healthineers Diasorin Myriad Genetics Hologic, Inc. bioMérieux FUJIFILM Holdings Corporation Quidel Exact Sciences Biocartis NV Cancer Diagnostics, Inc. (CDI) Amoy Diagnostics Bio-Rad Laboratories Bio SB, Inc. Vela Diagnostics CANCER TARGETED TECHNOLOGY LLC CancerIQ DNAmito Genetron Holdings Limited（Genetron Health） Metabiomics Novigenix SA Sienna Cancer Diagnostics - A BARD1 Life Sciences company Verily

Explore how Predicine's state-of-the-art liquid biopsy platforms provide comprehensive cancer analysis for treatment selection, response monitoring, and resistance detection in advanced HER2+ gastroesophageal adenocarcinoma patients. In collaboration with Dana-Farber Cancer Institute on the CAPOX BETR phase II trial, our innovative approach highlights the transformative impact of Predicine's ultra-sensitive genomic profiling, comprehensive methylation analysis, and whole genome based fragmentomic technologies in advancing personalized cancer care.    Key Highlights:  • HER2 Amplifications Accurately Detected in Plasma by PredicineCARE™.  • PredicineCARE™ and PredicineSCORE™ Predict Early Treatment Success.  • PredicineCARE™ ULTRA Monitors Resistance Mutations with Ultra-High Sensitivity.  • PredicineALERT™ Offers Comprehensive MRD Detection with whole Methylome Profiling    View the publication here: https://lnkd.in/dYW2_xXG   Predicine is committed to advancing cancer research and collaborates with leading pharmaceutical companies to transform insights into impactful therapies.    For more details about Predicine and out biopharma solutions, click below to schedule a meeting with the Predicine team: https://lnkd.in/gfAamv7U #diagnostics #oncology #NGS #liquidbiopsy #MRD #ctDNA #CDx 

IO360 is underway! Be sure to join us for tomorrow's panel discussion, State of the IO Market, Investments, and Deals: Investment Trends in IO, featuring Lumanity's Jeff Bockman. Connect with Jeff while at the conference or and reach out to contact@lumanity.com to schedule time to meet with us. #IO360nyc #Immunology #Oncology #Pharma #Biotech #ImmunoOncology #IO360

Please check our new publication in Nature Communications displaying technology innovation at Predicine in collaboration with Dana Farber to address treatment selection, response monitoring, and resistance detection in GEA. A great summary is shown below. #MRD #methylation #liquidbiopsy

Excited to be a part of the BIO International Convention in San Diego, a melting pot of transformative innovation and cutting-edge science. Alongside Marjorie Sidhoum, our VP of Business Development and Corporate Communication, we're immersed in the energy and enthusiasm of industry pioneers, entrepreneurs and investors - all focused advancing innovation in #biotechnology. At DOMAIN Therapeutics, we're driving innovation in the field of cancer treatment, pioneering novel therapeutic strategies that target GPCR mediated immunosuppression to beat resistance and defeat cancer. The pivotal role of GPCRs in restoring the immune responses against tumors and their modulation within the tumor microenvironment holds an immense potential to improve the efficacy of existing treatments. Our #immunooncology pipeline showcases a range of first-in-class and best-in-class assets. The EP4R antagonist, DT-9081, is progressing successfully through Phase I ascending dose clinical study in patients with advanced recurrent and metastatic solid tumors. Concurrently, our Treg-depleting ADCC/ADCP anti-CCR8 monoclonal antibody, DT-7012, is preparing for Phase I #clinicaltrials, anticipated to begin in early 2025. Additionally, PAR2 Negative Allosteric Modulator, DT-9045, is a first-in-class demonstrating a breakthrough mode of action and solid efficacy package in immuno-oncology. We are committed to revolutionizing GPCR #drugdiscovery and broadening therapeutic options for patients battling resistant cancers.  Join us to explore collaboration opportunities and how we can work together to push the boundaries of cancer treatment! #drugdevelopment #immunotherapy

I am thrilled to be joining the industry leaders, innovators and visionaries from around the globe at the upcoming BIO International Convention taking place in San Diego! Our Chief Scientific Officer Stephan Schann and I are eager to share Domain Therapeutics innovative work in pioneering immunotherapies offering a new hope for cancer patients unresponsive to other treatments. As a leading GPCR #immunooncology company, we are dedicated to revolutionizing cancer treatment by unveiling the full potential of GPCR modulation to beat cancer immunoresistance within the complex tumor microenvironment. Our innovative drug candidates are designed to make a difference, among these: Lead clinical candidate: ✔ DT-9081, a best-in-class EP4R antagonist, this small molecule targets prostaglandin E2 (PGE2) mediated resistance and is moving to Phase II #clinicaltrials. Currently in the pre-IND stage of development: ✔ DT-7012, a best-in-class Treg depleting anti-CCR8 monoclonal antibody that targets Treg mediated resistance and expected to start Phase I trials in early 2025 ✔ DT-9045, a first-in-class PAR2Negative Allosteric Modulator, small molecule with unique immuno-oncology potential Our innovative patient-centric approach enables us to restore immunocompetence and deliver the right medicine to the right sub-population of patients, redefining the future of #precisionmedicine and enhancing cancer treatment options. Keen to hear more about our pioneering work? Let’s connect! Schedule a meeting through the partnering platform. Together, we are unlocking the future of cancer therapies and paving the path to a healthier world through science and innovation. Join us on this journey! #biotechnology #drugdevelopment #partnerships Biotechnology Innovation Organization

Interested in learning about how mRNA is revolutionizing cancer therapy? Elsevier has made my Chapter 6: mRNA-based cancer therapeutics openly available here: https://bit.ly/AH_Ch_6 Explore the transformative use of IVT mRNA in cancer chemotherapy, with applications that include therapeutic cancer vaccines, personalized neoantigen vaccines, CAR T cell therapies, and immunostimulants. This chapter is from my newly released textbook “mRNA Therapeutics: Foundations, Innovations and Clinical Applications” Accessible here - https://bit.ly/AH_mRNA This textbook comprehensively describes mRNA as a disruptive new drug class, covering foundational concepts, key molecular engineering and delivery innovations, and current and future clinical applications of mRNA that are transforming medicine. #mRNATherapeutics #CancerImmunotherapy #CARTTherapy #PersonalizedNeoantigenVaccines #Biomedicine #Biotechnology #HealthInnovation Pfizer Moderna BioNTech SE

Starting the "Innovation and biomarkers in cancer drug development (IBCD) workshop" at the joint ENA meeting in Barcelona: EORTC - European Organisation for Research and Treatment of Cancer + National Cancer Institute (NCI) + American Association for Cancer Research This is a 3-hour workshop organized and chaired by Roberto Salgado from Belgium, co-chaired by David Solit, and Lyndsay Harris. There are 6 speakers followed by a panel discussion: Lindsay Renfro: Consdirations for biomarker-driven clinical trial designs in oncology Staci J Kearney, PhD, RAC: FDA's reform of regulations on laboratory developed tests (LDT's): The basics Joe Lennerz: FDA's oversight of laboratory developed tests (LDT's): Taming the wild west in daily practice Gabriel Bien-Willner: FDA's oversight of laboratory developed tests (LDT's): The perspective of payors Ina Christine Rondak: Can real world data replace control arms in prospective clinical trials? Role of the regulatory? and the Keynote-lecture by Kristina Jenei: How may Orbis 2.0 look like? Let's go. Meeting: https://lnkd.in/eYhHDic3 Link to program: https://lnkd.in/eYVi3JVr #biomarker #precisiononcology #drugdevelopment #FDA FDA BostonGene #LDT #digitalpathology #EMA European Medicines Agency #regulation #regulatoryscience #presonalized #statistics

🚀Revolutionizing Breast Cancer Treatment: Explore Our Cutting-Edge Antibodies and ADCs! 🎗️With 2.3M new cases and 670K fatalities yearly, breast cancer necessitates innovative solutions. Triple-negative breast Cancer (TNBC) presents formidable challenges, but our novel assets offer hope: ✔️ Bispecific ADCs like BCG023 & BCG033 show promising efficacy in preclinical studies.  ✔️ Monoclonal antibodies (mAbs) against Nectin-4, FGFR2b, CEACAM6, and ROR1 exhibit high target affinity and species cross-reactivity. Catch our poster C017 “Generation of a Fully Human Antibody Library and Novel Linker/Payload to Facilitate Development of Antibody-Drug Conjugates and Other Antibody-Based Therapeutics” at #PEGSBoston 2024 on May 16th or reach out for data and partnership opportunities: bd-licensing@biocytogen.com. #BreastCancer #Innovation #PEGSBoston2024 #antibodylibrary #renbiologics #drugdiscovery #TumorResearch #antibodytherapeutics #immunotherapy #cancerresearch #cancertherapy #bsab #bispecific